The beginning of 2023 will be a huge step to the US’s legalized psilocybin industry! Oregon Psilocybin Services (OPS), a new section housed within the Oregon Health Authority (OHA), will begin accepting license applications January 2, 2023. Oregon’s legalization and implementation of regulations will take three years altogether—several years may seem too long for the legalized psilocybin roll out, but better late than never. This should give the department plenty of time to draft, edit, edit some more, then implement the nation’s first regulatory framework for psilocybin.
The Oregon Health Authority (OHA), Public Health Division, has released their proposed psilocybin rules. These rules are necessary to execute the Oregon Psilocybin Services Act. The proposed rules began with how the adoption of the rules can impact racial equity, fiscal and economic impact,and the cost of compliance. The proposed rules include standards for the types of licenses, types of psilocybin products, cultivation and production standards, health and safety expectations for workers and end consumers, training curriculum requirements, product testing, and more. The proposed regulations have plenty of information, so for this blog Allay Consulting looks further into the licensing and manufacturing requirements within these regulations.
Licensing Types
Manufacturing Allowances and Restrictions
Species Allowance: There is a limitation on allowed species under the proposed regulations. The noted allowed species are only Psilocybe Cubensis. The proposed regulation further states, “Psilocybe Cubensis has been recommended as a safe species of fungi, and it is the only species allowed under the rules.” Psilocybe Cubensis is the most psychedelic mushroom species. Don’t fret–there are plenty (hundreds) of strains that fall under the Psilocybe Cubensis.
Cultivation Restrictions: Manufacturer licensees are prohibited from using manure and wood chips. Manufacturers may not produce psilocybin by using genetically modified organisms such as bacteria and may not produce psilocybin by chemical synthesis. Also, manufacturer licensees are prohibited from applying pesticides to fungi or to the fungi growing medium in any way.
Manufacturer Requirements: Manufacturing licensees must use food-grade equipment and other product-touching surfaces. These product-touching surfaces must be easily cleanable and safe to use in sanitary operations. Psilocybin products must have an assigned process lot and harvest lot unique ID number that are stored in a locked area. All process lot and harvest lot numbers must be entered into Oregon’s Psilocybin Tracking System. Similar to cannabis regulations, licensees cannot produce, transfer, or sell products that appeal to minors, products that are modeled after non-psilocybin products primarily consumed by minors, or products in the shape of animals, vehicles, persons, or characters.
Manufacturing Method Limitations: The proposed regulations place limitations on extraction methods to include water, vegetable glycerin, acetic acids, ethanol, and methanol as solvents in extraction. Other solvents are prohibited, with a specific notation that denatured alcohol is not allowed. The proposed regulations include further restrictions regarding pressure and heat: a manufacturer may not apply pressure or heat over 140 ᴼF when manufacturing psilocybin extracts.
Restrictions on Adulterants: The drafted regulations state, “a licensee may not add to psilocybin products any chemical, drug, plant, or substance that has the effect of altering potency, intoxicating effect, duration of effect, toxicity, or potential for excessive use, including but not limited to monoamine oxidase inhibitors (MAOIs), beverage alcohol, or cannabis. A psilocybin product that has added chemicals, drugs, plants, or substances that alter the potency, intoxicating effect, duration of effect, toxicity, or addictiveness is considered adulterated.”
Methods of Use: OHA has placed limitations on the type of psilocybin products allowed to include only orally ingestible products. Other methods such as transdermal patches, inhalers, nasal sprays, suppositories, and injections are prohibited.
Manufacturing Extraction Safety Measures: The licensee must have adequate ventilation controlling all sources of ignition where flammable vapors may be present, only use potable water if using water extraction method, install eye wash stations and emergency showers when working with solvents, provide personal protective equipment, and train their staff on the safety of extraction.
Manufacturing Records and Other Documentation: To no surprise, it’s proposed that manufacturer licensees are required to keep records of the following, including, but not limited to: manufacturing instructions; ingredients; procedures; solvents (use and handling); procedures for conducting necessary safety checks prior to commencing production; cleaning and sanitation; procedures for preventing growth of pathogenic organisms and toxin formations; proper disposal of any waste; and emergency procedures in case of fire, chemical spill, or other emergencies. Requiring basic current good manufacturing practice (cGMP) principles will result in more compliant products, which benefits both the industry (decreases liability) and the end consumer (decreases in safety issues and increases in quality!).
Required Testing: Similar to state level cannabis testing requirements, the proposed regulations include testing for psilocybin. Below is a list of the proposed testing requirements:
Still More to Consider
Now I know it seems amazing and exciting that there are actually regulations for psilocybin use being written, but there are major items being left out that may need to be addressed. Here are my top three examples of things that I believe should be addressed. Many people are discussing these items in the Oregon Psilocybin Advisory Board workgroup and in public comment. Whether they get addressed or not is still to be seen.
Unfortunately, these regulations are now closed to public comment. The Oregon Psilocybin Services Section will begin accepting applications for licensure on January 2, 2023. Until then, the Oregon Psilocybin Services Section is in a development period, working to build the nation's first regulatory framework for psilocybin services.
If you have any questions, comments or would like to join one of the Psilocybin Advisory Board Meetings, visit OHA’s Website for more information (1), or reach out to inquire using the information below.
Email Inquiries: OHA.Psilocybin@dhsoha.state.or.us
General Information Line: 971-341-1713
Reference
About the Author
Kim Stuck is the CEO and founder of Allay Consulting. Direct correspondence to: kim.stuck@allayconsulting.com.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.